Category Archives: People

ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is the next evolution of inflammasome inhibitors designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread […]

MINILUXE ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OF US$3.5 TO US$5 M (CAD $4.8M to CAD $6.0M)

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Company initiates non-brokered private placement at a premium to the market with substantial levels of the offering, already filled with signed commitments. Boston, MA, May 13, 2026 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX) (“MiniLuxe” or the “Company”), […]

Nasal Splints Market Size to be Worth USD 4.06 Billion by 2035; Growth is Driven by Increasing Number of Nasal Surgeries Globally | SNS Insider

U.S. Nasal Splints Market is expected to grow from USD 0.74 billion in 2025 to USD 1.16 billion in 2035 due to rising volumes of rhinoplasty Austin, May 13, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, The Nasal Splints Market size is valued at USD 2.46 Billion in 2025 and is projected to reach USD 4.06 […]

DutyFreeAlibaba.com and AlibabaDutyFree.com Announce Global Vendor, Wholesale & Investor Enrollment Ahead of Fall 2026 Launch

Bringing the Alibaba-Style Marketplace Concept to the Global Duty-Free World MIAMI, May 13, 2026 (GLOBE NEWSWIRE) — DutyFreeAlibaba.com and AlibabaDutyFree.com, two next-generation digital marketplace platforms under development, today announced the opening of early enrollment for vendors, suppliers, wholesalers, importers, distributors, premium brands, strategic partners, and investors ahead of their anticipated Fall 2026 B2C launch. In […]

Candel Therapeutics to Present at Upcoming Investor Conferences

NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) —  Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present and participate in one-on-one meetings […]

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at […]

Century Therapeutics Reports First Quarter Financial Results and Business Updates 

CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY‑813 preclinical data on June 8, 2026 On track to advance CNTY‑308, Century’s CD19‑targeted CAR‑iT cell […]

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of excellence Tel Aviv Sourasky Medical Center’s Helsinki Ethics Committee approves planned Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, marking an important clinical site […]

Dr. Jonathan Gavras Joins Healthmap Solutions as Chief Medical Officer

TAMPA, Fla., May 13, 2026 (GLOBE NEWSWIRE) — Healthmap Solutions (Healthmap), a leading kidney population health management company, has announced the appointment of Jonathan Gavras, MD, FCCP as Chief Medical Officer. Dr. Gavras is an experienced healthcare executive focused on improving healthcare performance and outcomes while driving innovation. Prior to joining Healthmap’s executive leadership team, […]